Pharmaceutical company
Appears in 1 story · Last updated Sep 9, 2026
As of September 2026: Running phase 2 trial of KIO-301 for retinitis pigmentosa
Blind mice given a new eye drop regained an instinct they had lost: avoiding bright areas. The drug, called prosthe6, restored light perception in animal models of age-related macular degeneration and retinitis pigmentosa within hours of a single dose. The treated mice avoided bright zones at light levels comparable to indoor lighting or a cloudy day.
Updated Sep 9
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
